ライフサイエンスコーパス: neurologic symptom

1 infarction, and all had consistent, acquired neurologic symptoms.

2 juni in their stools at the time of onset of neurologic symptoms.

3 9 patients with long COVID and self-reported neurologic symptoms.

4 eat potential neuroinvasive disease or other neurologic symptoms.

5 ed with viral suppression and improvement of neurologic symptoms.

6 s of patients with a variety of systemic and neurologic symptoms.

7 een sufficient to detect delayed or uncommon neurologic symptoms.

8 %, 7/185) were admitted to the ED because of neurologic symptoms.

9 ll as their propensity to seek treatment for neurologic symptoms.

10 lete the (177)Lu-PSMA-617 therapy because of neurologic symptoms.

11 the gut, and it is also related to renal and neurologic symptoms.

12 DTI), and if laterality of injury influences neurologic symptoms.

13 She denied any neurologic symptoms.

14 o a highly overlapping phenotype without the neurologic symptoms.

15 , in the other patient, resulted in improved neurologic symptoms.

16 with intellectual disability and progressive neurologic symptoms.

17 omyopathy 11 months prior to presentation of neurologic symptoms.

18 luding gastrointestinal, musculoskeletal and neurologic symptoms.

19 orresponding evidence by clinical imaging or neurologic symptoms.

20 ialosyl epitopes in the context of evocating neurologic symptoms.

21 ical manifestations include hypertension and neurologic symptoms.

22 ts, or gastrointestinal, musculoskeletal, or neurologic symptoms.

23 associated with bone, connective tissue, and neurologic symptoms.

24 R imaging of the brain for the evaluation of neurologic symptoms.

25 h rituximab and who subsequently develop new neurologic symptoms.

26 n of mutant animals and delayed the onset of neurologic symptoms.

27 ied an average of 13 days after the onset of neurologic symptoms.

28 ed in some cases with transient worsening of neurologic symptoms.

29 ppression, elevated liver enzyme levels, and neurologic symptoms.

30 vere xeroderma pigmentosum/Cockayne syndrome neurologic symptoms.

31 and 67% of patients younger than age 80 had neurologic symptoms.

32 tients have shown symptomatic improvement in neurologic symptoms, 1 patient has developed heart failu

33 The second most common reason was focal neurologic symptoms (16%); only 16% of these studies sho

34 rmed for gastrointestinal obstruction (34%), neurologic symptoms (23%), pain (12%), dyspnea (9%), jau

35 100% had gastrointestinal symptoms, 34% had neurologic symptoms, 43% had hemorrhagic manifestations,

36 9 D-CAA mutation carriers (M(+) ; 13 without neurologic symptoms, 6 with prior lobar intracerebral he

37 , conjunctivitis, headache, and other severe neurologic symptoms 7 to 24 hours after hemodialysis dre

38 Of 308 patients with acute neurologic symptoms, 73 met the inclusion criteria and w

39 Data examining specifically neurologic symptoms after (177)Lu-PSMA-617 treatment are

40 lidocaine to reduce the problem of transient neurologic symptoms after spinal blockade.

41 loads were detected in 42% of patients with neurologic symptoms and 44% of voluntary blood donors.

42 s suggest that the presence of preprocedural neurologic symptoms and a history of CAD are associated

43 tionship usually exists between the onset of neurologic symptoms and an infection or a vaccination.

44 Plaques associated with neurologic symptoms and asymptomatic plaques were compar

45 of immune response associated with distinct neurologic symptoms and cancers.

46 ic regression to evaluate the association of neurologic symptoms and examination findings with FM sta

47 otein COX7A1, which was also associated with neurologic symptoms and fatigue, as well as impairment i

48 The patient denies any neurologic symptoms and has no significant findings on n

49 with vision loss or diplopia accompanied by neurologic symptoms and in the absence of an intraocular

50 healthy subjects and 33 of 37 patients with neurologic symptoms and normal CSF and imaging studies c

51 tion carries a significant risk of transient neurologic symptoms and should be avoided.

52 f cyclovertical muscles, in association with neurologic symptoms and signs and with posterior fossa l

53 We report on 7 female patients with neurologic symptoms and signs including bilateral thalam

54 emporary symptomatic relief in patients with neurologic symptoms and signs related to mass effect fro

55 ith severe and persistent headache and other neurologic symptoms and signs should be considered for n

56 Twenty-nine patients (72%) experienced neurologic symptoms and were confirmed to have cerebral

57 tacts, 14 (11%) reported at least 1 abnormal neurologic symptom, and 9 (5%) had an abnormal neurologi

58 mboembolic events, seizures, fluctuations in neurologic symptoms, and adverse effects from corticoste

59 his hands and feet, with associated fevers, neurologic symptoms, and arthritis, who required hospita

60 erum levels of ferritin peaked with onset of neurologic symptoms, and higher ferritin levels were ass

61 ation leading to MMD-like occlusive lesions, neurologic symptoms, and neuron loss, whereas injured WT

62 ytopenia, microangiopathic hemolytic anemia, neurologic symptoms, and renal insufficiency, making the

63 , stage of disease, duration and severity of neurologic symptoms, and therapeutic intervention.

64 Neurologic symptoms are more severe and more likely to b

65 on post-COVID-19 status, neurologic and non-neurologic symptoms, as well as subjective and objective

66 n abnormal human HD gene (line R6/2) develop neurologic symptoms at 9-11 weeks of age through an unkn

67 Forty-three (52%) of the patients had neurologic symptoms at diagnosis.

68 The efavirenz group experienced more neurologic symptoms at week 1 (P < 0.001) but not at wee

69 Many patients with an LMNA mutation have neurologic symptoms by their 30s and develop progressive

70 ient with mantle-cell lymphoma who presented neurologic symptoms -clinically suggestive of ICANS- aft

71 g and occurs in two distinct forms, an acute neurologic symptom complex that occurs within hours or d

72 For neurologic symptoms (decreased alertness, falling asleep

73 s, in these experiments, the distribution of neurologic symptoms depends on the expression level and

74 Quantified HCHO was associated with neurologic symptoms (difficulty concentrating POR 1.47;

75 led trial, efavirenz use was associated with neurologic symptoms distinct from depression and anxiety

76 However, neurologic symptoms do not manifest until late stages of

77 For patients with fever or neurologic symptoms during summer and fall months, WNV s

78 y, characterized by the development of acute neurologic symptoms following CART infusion.

79 The pathophysiology of some neurologic symptoms following CART may therefore have a

80 st bacterial colonization and development of neurologic symptoms following infection by Brucella.

81 ay provide an anatomic basis for some of the neurologic symptoms found in FIV-infected cats and HIV-i

82 in the treatment of CNS metastases; however, neurologic symptoms frequently are not fully reversible,

83 primary nonrespiratory (gastrointestinal or neurologic) symptoms, had lung parenchymal findings susp

84 Neurologic symptoms have been observed not only during a

85 performed on 54853 patients with unexplained neurologic symptoms identified 1992 patients (4%) who we

86 available 1 week prior to the development of neurologic symptoms in 11 patients.

87 The presence of neurologic symptoms in aceruloplasminemia is unique amon

88 ing plerixafor had an increased incidence of neurologic symptoms in association with CNS infiltration

89 and using imputed data, less interference of neurologic symptoms in daily activities (P = .008) and f

90 er, LPL(-/-) mice developed much less severe neurologic symptoms in experimental autoimmune encephalo

91 opment is consistent with the development of neurologic symptoms in med and jolting mice, which have

92 ination is largely responsible for sustained neurologic symptoms in multiple sclerosis (MS).

93 Increased focus on neurologic symptoms in patients with rosacea may be warr

94 eloped into adulthood, did not develop overt neurologic symptoms in the first year of life, and had n

95 Some neurologic symptoms in the form of seizures and nystagmu

96 ients), new or worsening back pain (in 50%), neurologic symptoms (in 48%), nausea (in 39%), and stiff

97 Other neurologic symptoms included eye movement abnormalities

98 Preprocedural neurologic symptoms included transient ischemic attack,

99 Neurologic symptoms lasting at least 3 months were asses

100 e finding of immunity to Ma proteins is that neurologic symptoms may improve or resolve.

101 oronavirus disease 2019, 108 (15%) had acute neurologic symptoms necessitating neurologic imaging.

102 studies are best reserved for children with neurologic symptoms, neuropsychometric deficits, or elev

103 Although neurologic symptoms occur in two-thirds of lysosomal sto

104 Neurologic symptoms occurred in 38% of reports.

105 After logistic regression, the neurologic symptoms (odds ratio: 48.7, 95% confidence in

106 ction is one of the most important long-term neurologic symptoms of COVID-19, with the highest preval

107 concentrations but do not display the usual neurologic symptoms of hyperammonemia.

108 being applied to the study of the transient neurologic symptoms of the aura, as well as the painful

109 Median age at neurologic symptom onset was 42 years (range, 21-73 year

110 SCLC with untreated brain metastases without neurologic symptoms or asymptomatic with medical treatme

111 In patients without neurologic symptoms or central nervous system metastases

112 He denied neurologic symptoms or worsening of pain while lying dow

113 ), headache (OR 0.22; 95% CI 0.12-0.41), and neurologic symptoms (OR 0.1; 95% CI 0.19-0.49) as variab

114 re referred for feeding difficulties, subtle neurologic symptoms, or delayed psychomotor development

115 more likely to have BM >=1 cm (P < .001) and neurologic symptoms (P < .001) at presentation.

116 ar cardiac phenotype but a greater burden of neurologic symptoms (pain, numbness, tingling, and walki

117 siologic processes leading to development of neurologic symptoms, particularly in patients with syste

118 anthrax include the presence of nonheadache neurologic symptoms (positive likelihood ratio cannot be

119 Immediate neurologic symptoms postinjury were used to identify mil

120 nly seen in migraine patients with transient neurologic symptoms preceding their headaches, the so-ca

121 Neurologic symptoms present many years later.

122 None of the patients had ever experienced neurologic symptoms prior to the episode of optic neurit

123 stroke, transient ischemic attack, or other neurologic symptoms referable to the carotid arteries.

124 blood, and a higher likelihood of developing neurologic symptoms relative to animals lacking the IFN-

125 l brain lesions in patients with unexplained neurologic symptoms represents a challenge.

126 nce tomography or (2) panuveitis with 2 of 5 neurologic symptoms/signs.

127 yperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autis

128 Manganese exposure produces Parkinson's-like neurologic symptoms, suggesting a selective dysregulatio

129 The FM group had more neurologic symptoms than did the controls, with moderate

130 milarly, the FM group had significantly more neurologic symptoms than the control group in 27 of 29 c

131 ist therapy is supported by the worsening of neurologic symptoms that occurred in our index patient f

132 sible for COVID-19, is often associated with neurologic symptoms that range from mild to severe, yet

133 Neurologic symptoms that range in severity are common in

134 Among older patients and those with neurologic symptoms, the syndrome often progresses to re

135 7% of HIV-infected patients presenting with neurologic symptoms; the diagnosis of VZV-related CNS di

136 Although neurologic symptoms triggered by mild traumatic brain in

137 ght patients with preeclampsia-eclampsia and neurologic symptoms underwent magnetic resonance (MR) im

138 d cases demonstrate partial reversibility of neurologic symptoms upon restoration of CNS creatine lev

139 Median age at onset of neurologic symptoms was 58 (range, 27-83) years, and 87

140 ngth clinical MRI scans in participants with neurologic symptoms was performed.

141 lings (P=0.004), and the respective rates of neurologic symptoms were 4.0% and 9.4% (P=0.01).

142 The incidence of HAM/TSP and new signs and neurologic symptoms were computed in a group of patients

143 Changes in efavirenz-associated neurologic symptoms were correlated to efavirenz plasma

144 (177)Lu-PSMA-617 treatment, the most common neurologic symptoms were dysgeusia and dizziness.

145 pecialty appointments, with new or worsening neurologic symptoms were included in the study.

146 Neurologic symptoms were mild (dizziness) in 5 patients

147 Fifty-five new or worsening neurologic symptoms were observed in 50 patients (27%, 5

148 Preprocedural neurologic symptoms were present in 32%.

149 4 consecutive HIV-infected patients with new neurologic symptoms were tested for VZV DNA by a polymer

150 Neutropenia and neurologic symptoms were the most frequent reasons for e

151 s with newly diagnosed SLE, who had no focal neurologic symptoms, were studied.

152 model was instituted on animal's display of neurologic symptoms, which usually led to rapid demise.

153 Resolution of neurologic symptoms with initial steroid therapy, relaps

154 ed a febrile illness followed by progressive neurologic symptoms with presence of a vesiculopustular